BEFORE YOU BEGIN

COLLECT BLOOD

Blood Collection

INSERT BLOOD COLLECTOR

Keep

pushing!

Blood Dilution

SHAKE

INSERT CARTRIDGE

PREPARE SAMPLER

Blood Testing

Remove

INTO CARTRIDGE

DISPENSE SAMPLE

Push down completely to

dispense diluted sample

Remove quickly

5 MINUTES TO RESULTS


Display

REUSE MONITOR

 Run the test with all parts of the test kit at the same temperature 18°c within the specified (64 °F) range.

• If the kit has recently been at high temperatures (above 82°F) or in the refrigerator, keep the kit at room temperature for at least one hour before

• Avoid running the test in direct sunlight, on hot or cold surfaces, or near sources of heat or cold.



Venous Draw

Mix blood

testing

Collect blood from a slide

Just right

Too much

wipe away


excess

Too little

add more

blood

well before






Twisting

motion

helps



Stand Sampler on table


while preparing Cartridge





"Click" Test Cartridge into place








This result cycle remains displayed for 60 minutes or until the next Test Cartridge is inserted.

* If "QCOK" is not displayed, please see list of error codes on reverse side.



THE MONITOR IS REUSABLE To run another test, use a new

Sampler and Test Cartridge from the same kit and return to Step 1, "PREPARATION."



Use Monitor *only* with the materials display "00 TL."

of tests left

ALWAYS MATCH LOT NUMBERS

90839 B 3/2014


included in the original kit. The Monitor will expire after the programmed number of tests have been run. If another Test Cartridge is inserted, the Monitor will







Ensure Monitor is on level surface

Not fully inserte










* If not, Call Customer Service at 1-317-870-5610.

If you cannot resolve an error, please call Customer Service at 1-317-870-5610.

Do not handle


Monitor again until

test is complete!




6.3

A1C Now







0628216

A1C Now + PROFESSIONAL-USE PRODUCT INSERT

Intended Use

The A1CNow+® test provides quantitative measurement of the percent of alvoated hemoglobin (%A1C) levels in capillary (fingerstick) or venous whole blood samples. The a reusable, self-contained, integrated hand test is for professional use to monitor alvoemic control in people with diabetes.

Summary and Explanation

High levels of blood glucose result in overglycation of proteins throughout the body including hemoglobin. Glycation of hemoglobin can occur at the amino termini of the alpha and beta chains, as well as other sites with free amino groups.1 Hemoglobin A undergoes a slow glycation with glucose that is dependent on the time-average concentration of glucose over the 120-day life span of red blood cells.

The most prevalent and well-characterized species of glycated hemoglobin A is A1C, amount of A1C in the sample. making up approximately 3% to 6% of total hemoglobin in healthy individuals.1 The correlation of A1C and blood glucose levels make it a useful method of monitoring long-term blood glucose levels in people with diabetes.² Previous studies, such as the Diabetes Control

and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) used glycated hemoglobin as a way to measure overall glycemic control during the studies. These studies, and others, have shown that tight glycemic control is associated with fewer diabetes-related complications (e.g., vision problems, cardiovascular problems, and kidney problems).3 The National Glycohemoglobin Standardization Program (NGSP) was established to assure traceability of hemoglobin A1C (A1C) results to the DCCT. Studies show a direct relationship from %A1C to average blood glucose (MBG) levels. For every 1% change in A1C there is a change of about 30 mg/dl in MBG.4 The formula used to calculate the mean (average) blood glucose levels from the A1C levels is MBG = (31.7 x HbA1c) - 66.1. To convert to mean plasma glucose (MPG) use⁵ $MPG = MBG \times 1.11$. A1C can be measured by a variety of

techniques, and over the past decade they have be sure the finger is completely dry before expanded to include point-of-care assays. Point- lancing. of-care assays are well suited to environments such as healthcare providers' offices and clinics. because they are generally easy to perform, require no laboratory equipment, and provide rapid turn-around-time from sampling to result. This immediate feedback of results enhances provider/patient interaction and, therefore better enables disease management.

Principle of the Assav

Chek Diagnostics has developed an enabling technology that incorporates microelectronics. optics, and dry-reagent chemistry strips within held monitor and a single-use test cartridge. An unmeasured whole blood mixture (diluted) is directly applied to the sample port, and results are displayed in numeric form on the Monitor's liquid crystal display after 5 minutes. Having no switches or buttons, the Monitor self-activates upon insertion of the Test Cartridge. The A1CNow⁺ Monitor utilizes both immunoassay and chemistry technology to measure A1C and total hemoglobin, respectively. Upon the addition of a diluted blood sample, blue microparticles conjugated to anti-A1C antibodies migrate along the reagent strips. The amount of blue microparticles captured on the strips reflects the

For the total hemoglobin (Hb) portion of the test, the sample diluent converts Hb to met-Hb. The intensity of met-Hb color measured on the reagent strips is proportional to the concentration of hemoglobin in the sample. Test results are expressed as %A1C (A1C ÷ total Hb x 100).

Calibration of the A1CNow⁺ is performed with a set of blood samples that have been valueassigned by a National Glycohemoglobin Standardization Program (NGSP) certified laboratory using an NGSP reference method. Total Hb calibration values for those samples are obtained with a Total Hb analyzer (HemoCue Hemoglobin Test System, HemoCue, Inc., Lake Forest, CA). The calibration of the A1CNow+ test is thus traceable to the NGSP and to an NGSP Certified Network reference method.

Specimen Collection and Storage

Note: No fasting or special diet is necessary.

Fingerstick

The A1CNow+ test requires 5 microliters (µL) of whole blood (1 large drop), Fingerstick blood is obtained by standard techniques with any lancing system. If alcohol is used for cleansing.

Venipuncture/Sample Collection for

Venous blood should be collected into heparin up to 14 days in the refrigerator.

Warnings and Precautions

- 2. Carefully read and follow the Professional Procedure Guide to ensure proper test
- . If refrigerated, bring sealed pouches and Monitor to room temperature for one hour.
- 5. The Test Cartridges should not be used if the foil pouch is damaged.
- Add sample to A1CNow+ Test Cartridge within 2 minutes after pouch is opened.
- 7. All components of the A1CNow+ system are potentially biohazardous. Dispose of as biohazardous waste.
- . The Dilution Buffer in the Sampler contains ferricyanide in a buffered detergent solution. Do Not Ingest. In case of contact with skin or eyes, flush the area with large amounts of
- 9. Do not reuse Test Cartridges or Sample

Do not mix Monitors with Cartridges &

- Monitors, and Sample Dilution Kits may be stored at room temperature (18-28°C) for up to **four months** prior to use. Monitors, Test Cartridges, and Dilution Kits stored at room temperature must be thrown away if not used within the four months.
- If the temperature label, placed on the outside of every kit, is exposed to a temperature in excess of 122°F/50°C, the dot on the label will turn red and the product should not be used.
- The Monitors, Test Cartridges, and Sample Dilution Kits may be used until the expiration date printed on the box and pouches when stored refrigerated (2-8°C). Monitors. Test Cartridges, and Sample Dilution Kits stored in the refrigerator must be thrown away if not A1CNow+ operating and error codes used by the expiration date.
- Leave all components in their sealed pouches until use. If refrigerated, ensure pouches are at room temperature before use.

tubes (sodium or lithium, "green tops"). Blood samples should be well-mixed and tested at room temperature. Venous blood samples are stable for up to 8 hours at room temperature and

- For in vitro diagnostic use only.
- 4. The A1CNow+ Monitor and Test Cartridges

should not be used if either are cracked or

Sample Dilution Kits from different lots.

Kit Storage and Stability

- Pouched Test Cartridges, A1CNow+

Do not mix pouches and Monitors from

Package Components

- A1CNow+ Monitor (1)
- Sample Dilution Kit (10 or 20). each containing:
- detergent solution with ferricyanide
- Product insert (1)

- Fingerstick sample: lancet, or other blood
- Venous Sample: Heparin (sodium or lithium ["green top"]) preferred, venous collection
- Gauze pad or cotton ball
- Bandage
- Liquid control solution, Contact Customer controls that may be used.

Percent A1C monitors glucose control over the last three months. About 50% of the A1C result is from the past 30 days; about 25% is from the past 30-60 days and about 25% is from the past 60-120 days.1 Depending on the test methodology used, laboratory methods show that the reference range of the A1C test is approximately 4.0-6.5% A1C, and 6% to 9% in people with well to moderately controlled diabetes.1 Levels can be as high as 20% in people with poorly controlled diabetes.8 Canadian Diabetes Association's (CDA's) most recent Clinical Practice Guideline for diabetes specifies a treatment goal for patients in peneral of less than 7%.9

See the table below for a description of (OR = Out of Range; QC = Quality Control; E = Monitor Error)

IESSAGE DESCRIPTION AND RESOLUTION

OR 4

>13.0

QC 55 to 56

All other QC

The blood sample may have too little

not enough blood was collected, or

the Sampler.* You may wish to check

The blood sample may have too much

or excess blood was collected * You

or insufficient blood was collected.3

The blood sample may have too much

A1C, or excess blood was collected:

18°C (64°F). Repeat the test at room

The Monitor temperature is above

28°C (82°F). Repeat the test at room

Occurs when you insert a Test Cartridge

that already has sample added to it. Do

not remove and reinsert a Test Cartridge

Sample was added to Test Cartridge

down one test on the Monitor Remove

and discard Test Cartridge. To avoid this

error, do not add sample until the "WAIT

without sample addition for 2 minutes

after "SMPL" prompt. This counts down

are ready to dispense the Sampler.

initial reading. Be sure to remove the

dispensing it into the sample port, and

do not disturb the Monitor while the test

Insufficient sample was delivered to the

The quality control checks did not pass.

1-317-870-5610. The test will have to be

repeated with another Test Cartridge and

Sampler within one second after

Sampler and shake immediately

Call Customer Service at

The Monitor has a Fatal Error.

Call Customer Service toll-free at

Sample Dilution Kit.

1-317-870-5610

is runnina.*

one test on the Monitor, Discard the Test

Cartridge and insert a fresh one when you

The Monitor was unable to obtain a valid

The Test Cartridge remained in the Monitor

before "SMPL" display. This counts

prompt clears and "SMPI" appears

temperature (18-28°C).

temperature (18-28°C).

after adding sample.*

The %A1C is less than 4%.

The %A1C is greater than 13%.

hemoglobin (greater than 60% hemocrit)

may wish to check hemocrit by another

The blood sample may have too little A1C

the blood was not well mixed inside

hematocrit by another method.

hemoglobin (less than 20% hematocrit).

- A1CNow⁺ Test Cartridges (10 or 20) Each Test Cartridge includes the following chemistries: antibody to HbA1c, antigen conjugate that binds to the antibody, and membranes.
- Sampler (1) containing 0.37 ml of buffered
- Blood Collector (1)
- Patient result labels (10 or 20)

Materials Required but Not Supplied

- fingerstick collection device or,

- Service (1-317-870-5610) for a list of liquid

Result Interpretation

- This test is NOT for the screening or diagnosis of diabetes
- If the patient has high levels of Hemoglobin F, Hemoglobin S, Hemoglobin C, or other hemoglobin variants, the A1CNow system may report incorrect results.
- Any cause of shortened red cell survival (e.g., hemolytic anemia or other hemolytic diseases, pregnancy, recent significant blood loss, etc.) will reduce exposure of red cells to glucose. This results in a decrease in %A1C values. Percent A1C results are not reliable in patients with chronic blood loss and consequent variable erythrocyte life span.
- Rheumatoid Factor in high amounts will cause low results, or an error code. It is recommended that A1C be re-checked by alternate methodology such as boronate
- healthcare provider visits and blood glucose

This test is not a substitute for regular

As with any laboratory procedure, a large discrepancy between clinical impression and test results usually warrants investigation.

Each A1CNow+ Monitor performs over 50 internal chemical and electronic quality control checks, including potential hardware and software errors (e.g. cartridge alignment, programming), and potential reagent strip errors (e.g., insufficient sample volume. invalid calculations). The Monitor has been programmed to report an error code if these quality checks are not passed. Quality control testing should be performed at

- the following times: . With each new shipment.
- 2. With each new lot.
- Test Cartridge. To avoid this error be sure 3. With each new operator. to fully insert the Blood Collector into the
 - 4. Whenever problems (storage, operator, instrument, or other) are identified.
 - 5. To ensure that storage conditions have not affected the product, run a control sample before running a patient sample if the test kit has been stored for more than a month and it has been at least a month since the last control testing

*Carefully repeat the test using a new Test Cartridge and a new The measured value should be within the acceptable limits stated for the control mater If the results obtained are outside the accept limit, please review the procedure and re-test control material. If the measured value contin to fall outside the acceptable limit, please ref from analyzing additional patient samples and

contact Customer Service (1-317-870-5610). Good laboratory practices include a complete

quality control program. This entails proper sample collection and handling practices, ongoing training of testing personnel, ongoing evaluation of control results, proper storage of test kits, etc. A permanent record of control

results should be retained.

Expected Values (non-diabetic population

The expected normal range for %A1C using the A1CNow system was determined by testing blood samples from 118 presumptively nondiabetic individuals (fasting glucose levels <127 mg/dL) across three US sites. The population included 33 males and 85 females, and an age range from 19 to 76 with a mean age of 43. The mean %A1C result was 5.2% ±0.71% (1 SD). The 95% confidence limits were 3.9% to 6.5%. These values are similar to those reported in the literature. Each laboratory should determine its own reference range to conform to the population being tested.

Studies were performed to evaluate the linearity of the A1CNow system across its dynamic range. Clinical samples representing low and high %A1C levels were identified, and were mixed in various proportions into nine preparations. These samples were tested in replicates of at least five (n = 5). The observed results were compared to the expected results and analyzed in terms of percent recovery. The test is linear for %A1C levels between 4% and 13%, and produces reliable results with hematocrits between 20% and 60% packed cell volume (PCV).

Interference Testing/Specificity

of common test interferents, various common over-the-counter therapeutic agents, and oral antihyperglycemic agents commonly used to treat Type II diabetes. Two levels of %A1C (low and high, approximately 4% and 10%, respectively) were tested. See table below.

Studies were performed to assess the effect

t	INTERFERENT	TEST CONCENTR
	Bilirubin (unconjugated)	20 mg/dL
rial. table tt the nues frain	Triglyceride	3000 mg/dL
	Hemoglobin	500 mg/dL
	Acetaminophen	80 μg/mL
	Ascorbic acid	5 mg/dL
	Ibuprofen	120 μg/mL

TEST CONCENTRATIO Acetylsalicylic acid 1 mg/mL Glyburide 240 ng/mL (alibenclamide) Metformin (1.1-dimenthyl-25 μg/mL

The studies showed no effect from any of these potential interferents at concentrations up to approximately 5-times their normal levels or therapeutic doses.

Studies showed no interference from modified hemoglobins, including labile glycated hemoglobin when tested at two levels of %A1C (low and high, approximately 5% and 11% respectively). The modified hemoglobins, and the levels evaluated, were: labile hemoglobin with 1400 mg/dL glucose, carbamylated hemoglobin at a final concentration of 5 mM potassium cyanate, and acetylated hemoglobin at a final concentration of 14 mM acetylsalicylic

There were mixed results from the testing of high levels of Hemoglobin F, Hemoglobin S, and Hemoglobin C. Unreliable results may be obtained from patients with elevated levels of variant hemoglobins.

Precision testing was done under a specialized protocol. Following this protocol, two whole blood samples, one of approximately 6 %A1C (low), and one of approximately 9 %A1C (high), were tested over 20 days and four runs per day. for a total of 80 assays per level. The overall imprecision (including within-day and between day) was 3.00% CV at the low level and 4.02% CV at the high level.

Accuracy

diabetic and non-diabetic subjects across three US sites. Fingerstick sampling was performed on each subject for testing with A1CNow+, and venous blood was collected from each subject for comparative testing using an NGSP-certified method. A1CNow+ results were compared to the NGSP reference results. The A1C results ranged from 5.3 %A1C to 11.6%A1C, with a mean of 7.1 %A1C (reference results). Data analysis consisted of least squares linear regression (x = reference results) and bias calculation. The data are provided below.

Accuracy studies were conducted with 189

A1CNow+ Fingerstick Comparative

(NGSP-certified method is the Tosoh A1c 2.2)

Plus)			
n	112	Bias at 6% A1C (% difference)	6.05 (.83%)
Slope	1.04	Bias at 7% A1C (% difference)	7.09 (1.29%)
y- intercept	- 0.19	Bias at 9% A1C (% difference)	9.17 (1.89%)
"r"	0.97	Ava % diff	1 3/1%

The results showed that the accuracy of A1CNow+, with fingerstick samples was, on average, 99%. This means that, on average. a true 7 %A1C could read approximately 7.1

(NGSP-Certified method is the Tosoh

subjects, and each sample was tested on one of three different lots. Aliquots of the venous samples were also tested by the NGSP-certified method, providing comparative results. Data analysis again consisted of least squares linear regression (x = reference results) and bias calculation. The data are provided below.

n	110	Bias at 6% A1C (% difference)	5.95 (-0.8%)
Slope	1.03	Bias at 7% A1C (% difference)	6.98 (-0.3%)
y- intercept	-0.237	Bias at 8% A1C (% difference)	8.01 (+0.1%)
"r"	0.97	Avg. % diff.	-0.3%

A1CNow+ with venous sampling was, on average, 99.7% when matched aliquots of the samples were tested by an NGSP-certified reference method. A1CNow+ may be used with either fi ngerstick (capillary) or venous (heparinanticoagulated) whole blood samples.

The results showed that untrained users could Fogh-Anderson, N., D'Orazio, P. Proposal for standardizing perform A1CNow+ testing on themselves with the same accuracy as trained individuals. 7 Cagliero E Levina EV Nathan D.M. Immediate feedback

us)			
	112	Bias at 6% A1C (% difference)	6.05 (.83%)
ope	1.04	Bias at 7% A1C (% difference)	7.09 (1.29%)
tercept	- 0.19	Bias at 9% A1C (% difference)	9.17 (1.89%)

A1CNow+ Venous Comparative Testing

Venous blood was collected from 110 diabetic

		•	
n	110	Bias at 6% A1C (% difference)	5.95 (-0.8%)
Slope	1.03	Bias at 7% A1C (% difference)	6.98 (-0.3%)
y- intercept	-0.237	Bias at 8% A1C (% difference)	8.01 (+0.1%)
u,,,,	0.07	Ava 0/ diff	0.20/

The results showed that the accuracy of

direct-reading biosensors for blood glucose. Clin Chem 1998 44(3): 655-659 MLO Supplement, Point-of-Care Testing, 1992

References

treated type 2 diabetic patients. Diabetes Care 1999; 22(11): 8. Goldstein, D.E., Little, R.R., Wiedmeyer, H.M., et al. Glycated

RNATIONAL SYMBOLS

MANUFACTURER

CONTAINS SUFFICIENT FOR <n> TESTS

IN VITRO DIAGNOSTIC MEDICAL DEVICE

AUTHORIZED REPRESENTATIVE IN THE

TEMPERATURE LIMITATION

THIS PRODUCT FULFILS THE

BEQUIREMENTS OF DIRECTIVE 98/79EC

ON IN VITRO DIAGNOSTIC MEDICAL

CONSULT INSTRUCTIONS FOR USE

SEPARATE COLLECTION: BATTERIES MUST

BE DISPOSED OF IN ACCORDANCE WITH

COMPETENT LOCAL ADMINISTRATION

FOR INFORMATION ON THE REI EVANT

LAWS REGARDING DISPOSAL AND

RECYCLING IN YOUR AREA

1. Buris, C.A., Ashwood, E.R. Tietz Textbook of Clinical

Chemistry, 3rd Edition, W.B. Saunders Co., 1999.

2. Nathan, D.M., et al. The clinical information value of the

glycosylated hemoglobin assay. N Engl J Med 1984; 310

The Diabetes Control and Complications Trial Research

Group. The effect of intensive treatment of diabetes on the

evelopment and progression of longterm complication in

insulin-dependent diabetes mellitus. N Engl J Med 1993: 329:

American Diabetes Association, Standards of medical care for

patients with diabetes mellitus. Diabetes Care.1999; 22 (suppl

of A1C levels improves glycemic control in type 1 and insulin-

LAWS IN YOUR COUNTRY CONTACT YOUR

CATALOG NUMBER

BATCH CODE

DEVICES

CALITION

USE BY

Clin Chem 1986: 32: B64-B70. Canadian Diabetes Association 2008 Clinical Practice uidelines for the Prevention and Management of Diabetes in Canada, Sept. 2008, Vol. 32, (Suppl. 1).

hemoglobin: Methodologies and clinical applications.



Polymer Technology Systems, Inc. 7736 Zionsville Road Indianapolis IN 46268 LISA